CN106692075A - Less-impurity levo oxiracetam sterile powder and preparation method thereof - Google Patents
Less-impurity levo oxiracetam sterile powder and preparation method thereof Download PDFInfo
- Publication number
- CN106692075A CN106692075A CN201510458497.6A CN201510458497A CN106692075A CN 106692075 A CN106692075 A CN 106692075A CN 201510458497 A CN201510458497 A CN 201510458497A CN 106692075 A CN106692075 A CN 106692075A
- Authority
- CN
- China
- Prior art keywords
- oxiracetam
- levo
- minutes
- constant temperature
- warming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Less-impurity levo oxiracetam sterile powder is characterized in that the less-impurity levo oxiracetam sterile powder is prepared from levo oxiracetam, L-serine, mannitol, polyethylene glycol and Tween 80 as raw and accessory materials by the steps of concentrated distribution, dilute distribution, freeze drying and capping, the less-impurity levo oxiracetam injection sterile powder prepared by the method has a fixed shape, the process of freeze drying preparation is free of dry shrinkage and bubbling phenomenon, product homogeneity is good, lower layer and upper layer characters are consistent, impurities are less, the total impurities are less than 0.23%, the less-impurity levo oxiracetam sterile powder helps to improve the safety of drug use, and reduces adverse drug reactions, the product has good clarity, the turbidity of the product is lower than that of 0.5 # standard turbidity fluid, and has good stability, and the shelf life is up to 24 months.
Description
Technical field
The invention mainly relates to pharmaceutical technology field, and in particular to a kind of few levo-oxiracetam aseptic powdery of impurity and its
Preparation method.
Background technology
Oxiracetam (S-oxiracetam) is a kind of hydroxy-amino-butyric acid of synthesis (BABOB) cyclic derivatives, only
For central nervous system, cerebral cortex, hippocampus are mainly distributed on, have activation, protection or promote the function of nerve cell
Recover, improve the mnemonic learning function of disturbance of intelligence patient, and medicine in itself without direct vasoactive, also without in
Pivot excitation, the influence to ability of learning and memory is a kind of lasting facilitation.
The medicine was listed in 1987 in Italy, and the formulation of listing is tablet, 800mg；Capsule, 800mg；Parenteral solution,
1g/5ml.It is domestic at present there was only oxiracetam capsule and parenteral solution listing, and main active used is racemic modification.
The rush that Ye Lei etc. goes into a coma caused by mentioning levo-oxiracetam in the A patents of Publication No. CN 103735545 to alcoholism
Effect of waking up is obvious, and dextrorotation Oxiracetam is not acted on substantially, and the above-mentioned rush of levo-oxiracetam wakes up effect for racemization Aura
Western smooth 2 times；Levo-oxiracetam is notable to the promoting wakening of stupor caused by wound, anesthesia.Peak etc. is opened in publication number
It is big to traumatic brain injury caused by hydraulic pressure and freely falling body to disclose levo-oxiracetam in the patent of the A of CN 103599101
Mouse learning and memory cognition dysfunction improves significantly, and its drug effect is far above dextrorotation Oxiracetam.And
200mg/kg levo-oxiracetams are suitable with the effect of 400mg/kg Oxiracetams.Pharmacokinetic study results show：
Levo-oxiracetam and dextrorotation Oxiracetam are in beasle dog body without obvious chiral inversion.Beasle dog single intravenous injection gives
The main pharmacokinetic parameters of levo-oxiracetam nothing is substantially poor in blood plasma after left-handed and 2 multiple doses racemization Oxiracetam
It is different.The result of the tests such as safe pharmacology, anxious poison malicious, long show, under isodose level, levo-oxiracetam and Aura
It is western smooth to animal subject or the toxicity no significant difference of cell.Above-mentioned preclinical result of study shows, levo-oxiracetam
It is the main active that drug effect is played in Oxiracetam body, this product is used alone can reduce Clinical practice dosage, reduces latent
Toxicity.
Existing levo-oxiracetam aseptic powdery its be primarily present without solid shape, be difficult to be formed skeleton, easily there is drying shrinkage and
Bubbling phenomenon, product homogeneity is bad, and levels proterties is inconsistent, and clarity is unqualified, and stability is poor, and shelf life is short
The problems such as.
The content of the invention
It is aseptic it is an object of the invention to provide a kind of levo-oxiracetam few with solid form, good stability, impurity
Powder.
Preparation method another object of the present invention is to provide above-mentioned levo-oxiracetam aseptic powdery.
The purpose of the present invention is realized by following technical measures：
A kind of few levo-oxiracetam aseptic powdery of impurity, it is characterised in that it be with levo-oxiracetam as raw material,
A certain amount of excipient is added to be obtained；Wherein described excipient be sucrose, trehalose, mannitol, lactose, glucose,
Maltose, glucan, albumin, polyethylene glycol, glycerine, Serine, sodium glutamate, alanine, glycine,
One or more in methyl amimoacetic acid, phosphate, acetate, citrate, Tween 80.
Inventor has found to select a certain proportion of Serine, mannitol, poly- second two in composition described above by many experiments
Alcohol 2000 and Tween 80 composition Composite excipient, then coordinate specific preparation technology, may be such that above-mentioned levo-oxiracetam
Aseptic powdery has solid shape, easily forms skeleton, and product is less prone to drying shrinkage and bubbling phenomenon, and product clarity is improved,
And can extend shelf life.A kind of few levo-oxiracetam aseptic powdery of impurity, it is characterised in that it be with
Levo-oxiracetam, Serine, mannitol, polyethylene glycol, Tween 80 be supplementary material, according to concentrated compounding, it is dilute match somebody with somebody,
Freeze-drying, roll lid step be obtained；Wherein concentrated compounding step is that above-mentioned supplementary material is placed in container, adds left-handed Aura west
The sterilized water for injection stirring of smooth 10 times of weight portions, after dissolving, adds the needle-use activated carbon of mass fraction 0.5%, stirring
30min, is then filtered with 0.45 micrometer Millipore filter membrane, collects filtrate；Dilute is to adding sterile injection in filtrate with step
With water to recipe quantity, pH to 5.5 is adjusted with hydrochloric acid or NaOH, then with 0.22 micron of the degerming mistake of miillpore filter
Filter, takes that filtrate is qualified rear filling to be sub-packed in sterile glass vials；Freeze-drying step is quickly to be refrigerated to heat conduction oil temperature
- 40 DEG C, keep constant temperature 60 minutes, -10 DEG C are warming up to 5 DEG C/h, keep constant temperature 80 minutes, be quickly cooled to
- 40 DEG C, cryostat 120 minutes；Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；
0 DEG C is warming up to 4 DEG C/h, 0 DEG C of constant temperature 300 minutes；10 DEG C, 10 DEG C of 240 points of constant temperature are warming up to 5 DEG C/h
Clock, 30 DEG C are warming up to 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing,
It is lyophilized to terminate.
Most preferred above-mentioned levo-oxiracetam aseptic powdery, it is characterised in that it is by the former auxiliary of following significant percentage
Material is obtained：Levo-oxiracetam 52%~57%, Serine 13%~17%, mannitol 23%~28%, polyethylene glycol
2000 6%~8%, be placed in above-mentioned supplementary material in container by Tween 80 0.5%~1%, adds 10 times of levo-oxiracetam
The sterilized water for injection stirring of weight portion, after dissolving, adds the needle-use activated carbon of mass fraction 0.5%, stirs 30min,
Then filtered with 0.45 micrometer Millipore filter membrane, collect filtrate, to adding sterilized water for injection to recipe quantity in filtrate, use salt
Acid or NaOH regulation pH to 5.5, then with 0.22 micron of miillpore filter aseptic filtration, take the qualified rear filling of filtrate
Dress is sub-packed in sterile glass vials.Specific prescription proportioning, coordinates specific pH and specific supplementary material process step,
So that this quality is further improved.
A kind of preparation method of the few levo-oxiracetam aseptic powdery of impurity is worthy of careful study, it is characterised in that it is by as follows
Obtained in step：
1. concentrated compounding：The levo-oxiracetam of recipe quantity, excipient are placed in container, 10 times of weights of levo-oxiracetam are added
The sterilized water for injection stirring of part is measured, after dissolving, the needle-use activated carbon of mass fraction 0.5% is added, stirred
30min is mixed, is then filtered with 0.45 micrometer Millipore filter membrane, collect filtrate, it is standby；
2. it is dilute to match somebody with somebody：To sterilized water for injection to recipe quantity is added in filtrate, pH is adjusted to 5.5 with hydrochloric acid or NaOH,
Then with 0.22 micron of miillpore filter aseptic filtration, take that filtrate is qualified rear filling to be sub-packed in sterile glass
It is standby in bottle；
3. freeze-drying：It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, constant temperature is kept 60 minutes, with 5 DEG C/h of intensifications
To -10 DEG C, constant temperature is kept 80 minutes, be quickly cooled to -40 DEG C, cryostat 120 minutes；
Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；With 4 DEG C/
Hour is warming up to 0 DEG C, 0 DEG C of constant temperature 300 minutes；10 DEG C, 10 DEG C of perseverances are warming up to 5 DEG C/h
Temperature 240 minutes, 30 DEG C are warming up to 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case
Vacuum drop reaches 10Pa/10 timesharing, freezes and terminates；
4. lid is rolled：Aluminium-plastic combined cover needs once purged sterilizing, drying, then carries out rolling lid, obtains final product.
The present invention has following beneficial effect：
A kind of few levo-oxiracetam aseptic powdery of impurity of the present invention has solid shape, nothing is dry in lyophilized preparation process
Contracting and the phenomenon of bubbling, product homogeneity are good, and levels proterties is consistent, and impurity is few, and its total impurities is less than 0.23%, has
Beneficial to the security that medicine is used is improved, adverse drug reaction is reduced, product clarity is good, less than No. 0.5 standard turbidity
Liquid, good stability, shelf life is up to 24 months.
Specific embodiment
The present invention is specifically described below by embodiment, it is necessary to it is pointed out here that be that following examples are served only for
The present invention is further described, it is impossible to be interpreted as limiting the scope of the invention, without departing substantially from spirit of the invention
In the case of essence, the modification or replacement made to the inventive method, step or condition belong to the scope of the present invention.
Embodiment 1
A kind of few levo-oxiracetam aseptic powdery of impurity, is obtained according to the following steps：
| Composition | Consumption |
| Levo-oxiracetam | 100g |
| Serine | 29g |
| Mannitol | 50g |
| Polyethylene glycol 2000 | 12g |
| Tween 80 | 1g |
It is made 1000 bottles
Preparation process：
1. concentrated compounding：The levo-oxiracetam of recipe quantity, excipient are placed in container, 10 times of weights of levo-oxiracetam are added
The sterilized water for injection stirring of part is measured, after dissolving, the needle-use activated carbon of mass fraction 0.5% is added, stirred
30min is mixed, is then filtered with 0.45 micrometer Millipore filter membrane, collect filtrate, it is standby；
2. it is dilute to match somebody with somebody：To sterilized water for injection to recipe quantity is added in filtrate, pH is adjusted to 5.5 with hydrochloric acid or NaOH,
Then with 0.22 micron of miillpore filter aseptic filtration, take that filtrate is qualified rear filling to be sub-packed in sterile glass
It is standby in bottle；
3. freeze-drying：It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, constant temperature is kept 60 minutes, with 5 DEG C/h of intensifications
To -10 DEG C, constant temperature is kept 80 minutes, be quickly cooled to -40 DEG C, cryostat 120 minutes；
Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；With 4 DEG C/
Hour is warming up to 0 DEG C, 0 DEG C of constant temperature 300 minutes；10 DEG C, 10 DEG C of perseverances are warming up to 5 DEG C/h
Temperature 240 minutes, 30 DEG C are warming up to 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case
Vacuum drop reaches 10Pa/10 timesharing, freezes and terminates；
4. lid is rolled：Aluminium-plastic combined cover needs once purged sterilizing, drying, then carries out rolling lid, obtains final product.
Embodiment 2
A kind of few levo-oxiracetam aseptic powdery of impurity, is obtained according to the following steps：
| Composition | Consumption |
| Levo-oxiracetam | 100g |
| Serine | 23g |
| Mannitol | 41g |
| Polyethylene glycol 2000 | 11g |
| Tween 80 | 1.7g |
It is made 1000 bottles
Preparation process：Preparation technology according to embodiment 1 is obtained.
Embodiment 3
A kind of few levo-oxiracetam aseptic powdery of impurity, is obtained according to the following steps：
| Composition | Consumption |
| Levo-oxiracetam | 100g |
| Serine | 27g |
| Mannitol | 44g |
| Polyethylene glycol 2000 | 14g |
| Tween 80 | 1.5g |
It is made 1000 bottles
Preparation process：Preparation technology according to embodiment 1 is obtained.
Embodiment 4-6：A kind of few levo-oxiracetam aseptic powdery of impurity, is prepared by the supplementary material of following weight,
Preparation method is with embodiment 1：
| Embodiment | Levo-oxiracetam | Serine | Mannitol | Polyethylene glycol 2000 | Tween 80 |
| 4 | 100g | 25g | 42g | 12g | 1.1g |
| 5 | 100g | 26g | 43g | 11g | 1g |
| 6 | 100g | 27g | 46g | 13g | 1.5g |
In order to be better understood from the present invention, the beneficial of invention medicine is expanded on further below by way of stability test of the present invention
Effect, rather than limitation of the present invention.
Experiment one：A kind of few levo-oxiracetam aseptic powdery stability experiment of impurity of the present invention
Experiment material：
The Oxiracetam aseptic powdery sample of injection：For embodiment 1 is obtained
Acceleration study method：The Oxiracetam aseptic powdery of injection obtained in embodiment 1 is packed by listing, acceleration is put
In experimental box, certain hour sampling is tested to investigation project.
Acceleration study temperature：40±2℃
Humidity：RH75% ± 5%
The investigation time：0th, 1,2,3, June
Inspection target：Proterties, visible foreign matters, clarity, pH, relevant material, content, sterility test
Accelerated test stability is recorded：
Acceleration study result shows：Accelerate June sample suitable with 0 month sample items Testing index quality, show that this product adds
Speed experiment June, quality keeps stabilization, and this product stability is preferable.
Long-term experiment method：Injection Oxiracetam aseptic powdery obtained in embodiment 1 is packed by listing, is put and is stayed for a long time
In sample case, certain hour sampling is tested to investigation project.
Acceleration study temperature：25±2℃
Humidity：RH60% ± 10%
The investigation time：0th, 3,6,9,12,18,24 months
Inspection target：Proterties, visible foreign matters, clarity, pH, relevant material, content, sterility test
Long term test stability is recorded：
Long term test shows：24 months proterties of this product long term test, visible foreign matters, clarity, pH value, relevant material,
Content and sterility test indices without significant changes, meet the related rule of items of production quality standard draft
It is fixed.24 months steady qualities of this product long term test, therefore minimum 24 months of this product shelf life, long term test still is continuing to examine
During examining.
Claims (3)
1. the few levo-oxiracetam aseptic powdery of a kind of impurity, it is characterised in that it is, with levo-oxiracetam, Serine, mannitol, polyethylene glycol, Tween 80 as supplementary material, according to concentrated compounding, dilute to match somebody with somebody, freeze-drying, roll lid step and be obtained；Wherein concentrated compounding step is that above-mentioned supplementary material is placed in container, the sterilized water for injection stirring of 10 times of weight portions of levo-oxiracetam is added, after dissolving, add the needle-use activated carbon of mass fraction 0.5%, stirring 30min, is then filtered with 0.45 micrometer Millipore filter membrane, collects filtrate；Dilute is, to adding sterilized water for injection to recipe quantity in filtrate, pH to 5.5 being adjusted with hydrochloric acid or NaOH, then with 0.22 micron of miillpore filter aseptic filtration, to take that filtrate is qualified rear filling to be sub-packed in sterile glass vials with step；Heat conduction oil temperature is refrigerated to -40 DEG C by freeze-drying step for quick, keeps constant temperature 60 minutes, and -10 DEG C are warming up to 5 DEG C/h, keeps constant temperature 80 minutes, is being quickly cooled to -40 DEG C, cryostat 120 minutes；Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C is warming up to 4 DEG C/h, 0 DEG C of constant temperature 300 minutes；10 DEG C are warming up to 5 DEG C/h, 10 DEG C of constant temperature 240 minutes is warming up to 30 DEG C with 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing, is freezed and terminated.
2. levo-oxiracetam aseptic powdery as claimed in claim 1, it is characterised in that it is obtained by the supplementary material of following significant percentage：Levo-oxiracetam 52% ~ 57%, Serine 13% ~ 17%, mannitol 23% ~ 28%, polyethylene glycol 2000 6% ~ 8%, Tween 80 0.5% ~ 1%, above-mentioned supplementary material is placed in container, add the sterilized water for injection stirring of 10 times of weight portions of levo-oxiracetam, after dissolving, add the needle-use activated carbon of mass fraction 0.5%, stirring 30min, then filtered with 0.45 micrometer Millipore filter membrane, collect filtrate, to addition sterilized water for injection in filtrate to recipe quantity, pH to 5.5 is adjusted with hydrochloric acid or NaOH, then with 0.22 micron of miillpore filter aseptic filtration, take that filtrate is qualified rear filling to be sub-packed in sterile glass vials.
3. the preparation method of the few levo-oxiracetam aseptic powdery of a kind of impurity as claimed in claim 1 or 2, it is characterised in that it is obtained as follows：
A. concentrated compounding：The levo-oxiracetam of recipe quantity, excipient are placed in container, the sterilized water for injection stirring of 10 times of weight portions of levo-oxiracetam are added, after dissolving, the needle-use activated carbon of mass fraction 0.5% is added, 30min is stirred, is then filtered with 0.45 micrometer Millipore filter membrane, filtrate is collected, it is standby;
B. it is dilute to match somebody with somebody：To adding sterilized water for injection to recipe quantity in filtrate, pH to 5.5 is adjusted with hydrochloric acid or NaOH, then with 0.22 micron of miillpore filter aseptic filtration, take filtrate it is qualified it is rear it is filling be sub-packed in sterile glass vials, it is standby；
C. freeze-drying：It is quick that heat conduction oil temperature is refrigerated to -40 DEG C, keep constant temperature 60 minutes, -10 DEG C are warming up to 5 DEG C/h, keep constant temperature 80 minutes, it is being quickly cooled to -40 DEG C, cryostat 120 minutes；Then drying is vacuumized, is warming up to 10 DEG C/h, -10 DEG C of constant temperature 150 minutes；0 DEG C is warming up to 4 DEG C/h, 0 DEG C of constant temperature 300 minutes；10 DEG C are warming up to 5 DEG C/h, 10 DEG C of constant temperature 240 minutes is warming up to 30 DEG C with 10 DEG C/h, 30 DEG C of constant temperature 60 minutes, while preceding case vacuum drop reaches 10Pa/10 timesharing, is freezed and terminated；
D. lid is rolled：Aluminium-plastic combined cover needs once purged sterilizing, drying, then carries out rolling lid, obtains final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510458497.6A CN106692075A (en) | 2015-07-30 | 2015-07-30 | Less-impurity levo oxiracetam sterile powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510458497.6A CN106692075A (en) | 2015-07-30 | 2015-07-30 | Less-impurity levo oxiracetam sterile powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106692075A true CN106692075A (en) | 2017-05-24 |
Family
ID=58900937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510458497.6A Pending CN106692075A (en) | 2015-07-30 | 2015-07-30 | Less-impurity levo oxiracetam sterile powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692075A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766597A (en) * | 2008-12-31 | 2010-07-07 | 北京利乐生制药科技有限公司 | Injection preparation with levo-oxiracetam as active component |
-
2015
- 2015-07-30 CN CN201510458497.6A patent/CN106692075A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766597A (en) * | 2008-12-31 | 2010-07-07 | 北京利乐生制药科技有限公司 | Injection preparation with levo-oxiracetam as active component |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105434373B (en) | A kind of injection Oxiracetam lyophilized preparation and preparation method thereof | |
| CN106692075A (en) | Less-impurity levo oxiracetam sterile powder and preparation method thereof | |
| CN106692077A (en) | Levo oxiracetam lyophilized powder for injection and preparation method thereof | |
| CN107281135A (en) | A kind of injection levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281118A (en) | Good levo-oxiracetam freeze-dried powder of a kind of stability and preparation method thereof | |
| CN107281122A (en) | A kind of levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281120A (en) | A kind of levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281119A (en) | Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof | |
| CN107281132A (en) | A kind of impurity is few（S）Oxo-1-pyrrolidine ethanamide aseptic powdery of -4- hydroxyls -2 and preparation method thereof | |
| CN107281137A (en) | Oxo-1-pyrrolidine ethanamide freeze-dried powder of one kind (S) -4- hydroxyls -2 and preparation method thereof | |
| CN107281131A (en) | A kind of stability is good（S）Oxo-1-pyrrolidine ethanamide freeze-dried powder of -4- hydroxyls -2 and preparation method thereof | |
| CN106389349A (en) | L-oxiracetam freeze drying powder for injection, and preparation method thereof | |
| CN107281128A (en) | Few levo-oxiracetam aseptic powdery of a kind of impurity and preparation method thereof | |
| CN106692074A (en) | Good-stability freeze-dried powder injection of L-oxiracetam and preparation method thereof | |
| CN105726495B (en) | A kind of short-acting benzodiazepine salt pharmaceutical composition of injection and preparation method thereof | |
| CN107281123A (en) | It is a kind of（S）Oxo-1-pyrrolidine ethanamide freeze-dried powder of -4- hydroxyls -2 and preparation method thereof | |
| CN106377512A (en) | S-oxiracetam freeze-dried powder for injection and preparation method thereof | |
| CN107281121A (en) | A kind of injection（S）Oxo-1-pyrrolidine ethanamide freeze-dried powder of -4- hydroxyls -2 and preparation method thereof | |
| CN106377511A (en) | S-oxiracetam sterile injectable powder and preparation method thereof | |
| CN107281140A (en) | Oxo-1-pyrrolidine ethanamide aseptic powdery injection of one kind (S) -4- hydroxyls -2 and preparation method thereof | |
| CN107281139A (en) | Good levo-oxiracetam freeze-dried powder of a kind of stability and preparation method thereof | |
| CN107281130A (en) | A kind of levo-oxiracetam aseptic powdery injection and preparation method thereof | |
| CN107281116A (en) | It is a kind of（S）Oxo-1-pyrrolidine ethanamide aseptic powdery injection of -4- hydroxyls -2 and preparation method thereof | |
| CN107281114A (en) | A kind of injection levo-oxiracetam freeze-dried powder and preparation method thereof | |
| CN107281133A (en) | A kind of levo-oxiracetam freeze-dried powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170824 Address after: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 400030 Chongqing city Shapingba District Yubei Road No. 50 of No. 13-15-6A Applicant before: DONGZE PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |